STR-P004

STR-P004 is an **in vivo chimeric antigen receptor (CAR) T cell therapy** under early clinical development by Starna Therapeutics for the treatment of CD19-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma. Unlike standard CAR-T, which requires ex vivo cell engineering and reinfusion, in vivo CAR-T therapy like STR-P004 aims to deliver genetic instructions directly into the patient, inducing their T cells to express a CAR targeting CD19. This potentially simplifies manufacturing and expands access to CAR-T therapy. The therapy is being tested in a dose-escalation trial in patients with relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma, with a primary focus on safety, tolerability, pharmacokinetics, and preliminary antitumor activity[1][2][3][4][5].